PROTAC Drug Development & Testing

Accelerate Your Drug Development With Southern Research

SR-PROTAC-Hero-1

PROTAC Programs at Southern Research

Southern Research is a leading contract research organization (CRO) that specializes in the development and testing of PROTACs. We have a team of experienced scientists and researchers who are experts in all aspects of PROTAC drug discovery and development, including:

  • Target identification and validation
  • PROTAC design and synthesis
  • In vitro and in vivo testing of PROTACs
  • Assessment of the safety and efficacy of PROTACs

We offer a comprehensive range of PROTAC drug development and testing services, including:

Feasibility studies: We can help you assess the feasibility of developing a PROTAC for your target disease.
Lead optimization: We can help you optimize your PROTAC lead compound to improve its safety and efficacy.
Preclinical testing: We can conduct all of the necessary preclinical testing to evaluate the safety and efficacy of your PROTAC drug candidate in animal models.
Manufacturing development: We can help you develop a manufacturing process for yourPROTAC drug candidate so that it can be produced at scale for clinical trials.

If you are developing a PROTAC drug candidate, we encourage you to contact us to learn more about how we can help you accelerate your drug development program.

Selectively Target and Destroy Disease-Causing Proteins

PROTAC drugs, or proteolysis-targeting chimeras, are a new class of drugs that work by hijacking the cell’s own degradation machinery to destroy unwanted proteins. PROTAC drugs are made up of three components:

    • A ligand that binds to the target protein
    • A ligand that binds to an E3 ubiquitin ligase
    • A linker that connects the two ligands

The PROTAC drug binds to the target protein and the E3 ubiquitin ligase, bringing the two molecules together. The E3 ubiquitin ligase then ubiquitinates the target protein, which marks it for degradation by the proteasome. PROTAC drugs have a number of advantages over traditional drugs:

    • PROTAC drugs can target proteins that are difficult to target with traditional drugs, such as undruggable proteins and proteins that are involved in signaling pathways.
    • PROTAC drugs are highly specific, which means that they are less likely to cause side effects.
    • PROTAC drugs are effective at low doses.
    • PROTAC drugs are still under development, but they have the potential to revolutionize the treatment of a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Here are some examples of diseases that could be treated with PROTAC drugs:

    • Cancer: PROTAC drugs could be used to target a variety of cancer-causing proteins, such as oncoproteins and tumor suppressors.
    • Neurodegenerative diseases: PROTAC drugs could be used to target proteins that are involved in the development of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease.
    • Autoimmune diseases: PROTAC drugs could be used to target proteins that are involved in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

PROTAC drugs are a promising new class of drugs with the potential to improve the lives of many patients.

Basic Template Image

© 2024 Southern Research. All rights reserved.